167 related articles for article (PubMed ID: 9694160)
1. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors.
Martiniello-Wilks R; Garcia-Aragon J; Daja MM; Russell P; Both GW; Molloy PL; Lockett LJ; Russell PJ
Hum Gene Ther; 1998 Jul; 9(11):1617-26. PubMed ID: 9694160
[TBL] [Abstract][Full Text] [Related]
2. Transcription-targeted gene therapy for androgen-independent prostate cancer.
Martiniello-Wilks R; Tsatralis T; Russell P; Brookes DE; Zandvliet D; Lockett LJ; Both GW; Molloy PL; Russell PJ
Cancer Gene Ther; 2002 May; 9(5):443-52. PubMed ID: 11961667
[TBL] [Abstract][Full Text] [Related]
3. Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors.
Lockett LJ; Molloy PL; Russell PJ; Both GW
Clin Cancer Res; 1997 Nov; 3(11):2075-80. PubMed ID: 9815599
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models.
Eastham JA; Chen SH; Sehgal I; Yang G; Timme TL; Hall SJ; Woo SL; Thompson TC
Hum Gene Ther; 1996 Mar; 7(4):515-23. PubMed ID: 8800746
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models.
Voeks D; Martiniello-Wilks R; Madden V; Smith K; Bennetts E; Both GW; Russell PJ
Gene Ther; 2002 Jun; 9(12):759-68. PubMed ID: 12040457
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus.
Wang XY; Martiniello-Wilks R; Shaw JM; Ho T; Coulston N; Cooke-Yarborough C; Molloy PL; Cameron F; Moghaddam M; Lockett TJ; Webster LK; Smith IK; Both GW; Russell PJ
Gene Ther; 2004 Nov; 11(21):1559-67. PubMed ID: 15343359
[TBL] [Abstract][Full Text] [Related]
7. In vivo adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing pancreatic cancer.
Ohashi M; Kanai F; Tanaka T; Lan KH; Shiratori Y; Komatsu Y; Kawabe T; Yoshida H; Hamada H; Omata M
Jpn J Cancer Res; 1998 Apr; 89(4):457-62. PubMed ID: 9617353
[TBL] [Abstract][Full Text] [Related]
8. Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer.
Martiniello-Wilks R; Wang XY; Voeks DJ; Dane A; Shaw JM; Mortensen E; Both GW; Russell PJ
J Gene Med; 2004 Dec; 6(12):1343-57. PubMed ID: 15493036
[TBL] [Abstract][Full Text] [Related]
9. Recombinant AAV-mediated HSVtk gene transfer with direct intratumoral injections and Tet-On regulation for implanted human breast cancer.
Li ZB; Zeng ZJ; Chen Q; Luo SQ; Hu WX
BMC Cancer; 2006 Mar; 6():66. PubMed ID: 16539746
[TBL] [Abstract][Full Text] [Related]
10. Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease.
Martiniello-Wilks R; Dane A; Voeks DJ; Jeyakumar G; Mortensen E; Shaw JM; Wang XY; Both GW; Russell PJ
J Gene Med; 2004 Jan; 6(1):43-54. PubMed ID: 14716676
[TBL] [Abstract][Full Text] [Related]
11. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
12. Suppression of murine mammary carcinoma growth and metastasis by HSVtk/GCV gene therapy using in vivo electroporation.
Shibata MA; Morimoto J; Otsuki Y
Cancer Gene Ther; 2002 Jan; 9(1):16-27. PubMed ID: 11916241
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
14. Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan.
Wildner O; Blaese RM; Morris JC
Hum Gene Ther; 1999 Nov; 10(16):2679-87. PubMed ID: 10566896
[TBL] [Abstract][Full Text] [Related]
15. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer.
Wildner O; Morris JC; Vahanian NN; Ford H; Ramsey WJ; Blaese RM
Gene Ther; 1999 Jan; 6(1):57-62. PubMed ID: 10341876
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene.
Mohr L; Shankara S; Yoon SK; Krohne TU; Geissler M; Roberts B; Blum HE; Wands JR
Hepatology; 2000 Mar; 31(3):606-14. PubMed ID: 10706550
[TBL] [Abstract][Full Text] [Related]
17. Experimental study of the RV-HSV-TK/GCV suicide gene therapy system in gastric cancer.
Tang Q; Zhang D; Wan M; Jin L
Cancer Biother Radiopharm; 2007 Dec; 22(6):755-61. PubMed ID: 18158766
[TBL] [Abstract][Full Text] [Related]
18. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.
Herman JR; Adler HL; Aguilar-Cordova E; Rojas-Martinez A; Woo S; Timme TL; Wheeler TM; Thompson TC; Scardino PT
Hum Gene Ther; 1999 May; 10(7):1239-49. PubMed ID: 10340555
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer.
Anderson LM; Swaminathan S; Zackon I; Tajuddin AK; Thimmapaya B; Weitzman SA
Gene Ther; 1999 May; 6(5):854-64. PubMed ID: 10505111
[TBL] [Abstract][Full Text] [Related]
20. Targeted gene therapy of ovarian cancer using an ovarian-specific promoter.
Bao R; Selvakumaran M; Hamilton TC
Gynecol Oncol; 2002 Feb; 84(2):228-34. PubMed ID: 11812079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
